MeiraGTx (MGTX) Soars 6.8%: Is Further Upside Left in the Stock?
Summarize this article with:
AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA Stocks MeiraGTx (MGTX) Soars 6.8%: Is Further Upside Left in the Stock? April 20, 2026 — 06:53 am EDT Written by Zacks Equity Research for Zacks-> MeiraGTx Holdings PLC (MGTX) shares ended the last trading session 6.8% higher at $10.12. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 29% gain over the past four weeks.The price rise can be attributed to growing investor confidence related to MeiraGTx’s promising late-stage clinical programs, including Parkinson's disease, radiation-induced xerostomia, X-linked retinitis pigmentosa and AIPL1-associated retinal dystrophy. These programs use targeted local delivery of small doses of genetic medicines to treat both inherited and more common conditions with severe unmet need.This company is expected to post quarterly loss of $0.62 per share in its upcoming report, which represents a year-over-year change of -21.6%. Revenues are expected to be $1.55 million, down 19.7% from the year-ago quarter.Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.For MeiraGTx, the consensus EPS estimate for the quarter has been revised 4.5% lower over the last 30 days to the current level. And a negative trend in earnings estimate revisions doesn't usually translate into price appreciation. So, make sure to keep an eye on MGTX going forward to see if this recent jump can turn into more strength down the road.The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>MeiraGTx is a member of the Zacks Medical - Biomedical and Genetics industry. One other stock in the same industry, Ocugen (OCGN), finished the last trading session 3.1% higher at $1.99. OCGN has returned -13.8% over the past month.Ocugen's consensus EPS estimate for the upcoming report has changed +5.9% over the past month to -$0.05. Compared to the company's year-ago EPS, this represents no change. Ocugen currently boasts a Zacks Rank of #3 (Hold).
Radical New Technology Could Hand Investors Huge Gains Quantum Computing is the next technological revolution, and it could be even more advanced than AI. While some believed the technology was years away, it is already present and moving fast. Large hyperscalers, such as Microsoft, Google, Amazon, Oracle, and even Meta and Tesla, are scrambling to integrate quantum computing into their infrastructure.
Senior Stock Strategist Kevin Cook reveals 7 carefully selected stocks poised to dominate the quantum computing landscape in his report, Beyond AI: The Quantum Leap in Computing Power. Kevin was among the early experts who recognized NVIDIA's enormous potential back in 2016. Now, he has keyed in on what could be "the next big thing" in quantum computing supremacy. Today, you have a rare chance to position your portfolio at the forefront of this opportunity.See Top Quantum Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportMeiraGTx Holdings PLC (MGTX) : Free Stock Analysis ReportOcugen, Inc. (OCGN) : Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Tags Stocks Zacks Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com. More articles by this source-> Stocks mentioned MGTX OCGN More Related Articles This data feed is not available at this time. Data is currently not available • Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.